PATH TO PEPTIDES PT-141:

A DIFFERENT APPROACH TO SEXUAL HEALTH RESEARCH

The first new class of sexual health compound in over 20 years works through the brain, not blood flow. Here’s the science.

FOR OVER TWO DECADES, EVERY SEXUAL HEALTH MEDICATION WORKED THE SAME WAY — BY INCREASING BLOOD FLOW. THEN RESEARCHERS DISCOVERED A PEPTIDE THAT WORKS THROUGH AN ENTIRELY DIFFERENT PATHWAY: THE BRAIN’S DESIRE CIRCUITRY.

Bremelanotide (brand name Vyleesi), derived from the research peptide PT-141, became the first FDA-approved sexual health medication that targets the central nervous system rather than blood vessels. Its story — from a sunless tanning experiment to an FDA-approved drug — is one of the most unusual in pharmaceutical history.

WHY THIS MATTERS

Sexual health disorders are far more common than most people realize. Hypoactive sexual desire disorder (HSDD) — persistently low sexual desire that causes distress — affects approximately
10% of adult women.1

Erectile dysfunction affects roughly 30 million American men, with rates increasing with age.2 While medications like sildenafil (Viagra) work well for many, they don’t help everyone — particularly those whose difficulties stem from desire rather than physical function.

That gap — between medications that improve blood flow and the need for treatments that address desire itself — is where PT-141 and bremelanotide fit in.

THE SCIENCE: THE MELANOCORTIN SYSTEM

PT-141 works through something called the melanocortin system — a network of receptors in the brain that influence multiple functions including skin pigmentation, appetite, inflammation,
and sexual arousal.3

Think of the melanocortin system like a switchboard in your brain. Different switches (called MC receptors, numbered MC1R through MC5R) control different functions. PT-141 primarily activates the MC4R receptor, which is heavily involved in sexual arousal and desire.4

Here’s what makes this approach fundamentally different from Viagra-type drugs:

THE ACCIDENTAL DISCOVERY

The PT-141 story starts with a sunless tanning experiment. In the 1990s, researchers at the University of Arizona were testing Melanotan II — a synthetic peptide designed to stimulate
melanin production (skin darkening) without UV exposure.5

During clinical testing, a surprising side effect emerged: many participants reported spontaneous sexual arousal. This was unexpected. The researchers realized the peptide was activating
MC4R receptors in the brain alongside the MC1R receptors that control skin color.6

Scientists then modified the molecule to focus specifically on the sexual arousal effects while minimizing the tanning effects. The result was PT-141, later developed into the pharmaceutical drug bremelanotide (Vyleesi).

Key Distinction: PT-141 is the research peptide. Bremelanotide (Vyleesi) is the FDA-approved pharmaceutical derived from it. They are closely related but not identical. Vyleesi is the only
FDA-approved version for clinical use.

WHAT THE CLINICAL RESEARCH SHOWS

IN WOMEN (HSDD)

The FDA approval of bremelanotide was based on two large Phase 3 trials called RECONNECT. These studied over 1,200 premenopausal women with HSDD.7

Results showed that women using bremelanotide experienced a significant increase in sexual desire and a significant decrease in distress related to low desire, compared to placebo. The
improvement was seen as early as the first use and maintained over the 24-week study period.8

IN MEN (ERECTILE DYSFUNCTION)

Research in men has been more limited but intriguing. Early trials showed that PT-141 produced erections in men with erectile dysfunction — including some men who had not responded to
sildenafil (Viagra).9

A study published in Urology found that PT-141 was effective in men with both organic and psychogenic erectile dysfunction. Because it works through the brain rather than blood flow, researchers believe it may help patients whose ED has psychological or neurological components.10

SAFETY CONSIDERATIONS

The most common side effects reported in clinical trials were nausea (about 40% of users), flushing, and headache. The nausea was usually mild and decreased with repeated use.11

Bremelanotide can cause a transient increase in blood pressure. The FDA label includes a warning against use in patients with uncontrolled high blood pressure or known cardiovascular
disease.12

Safety Note on Melanotan II: The precursor compound Melanotan II is NOT FDA-approved and has been associated with safety concerns including nausea, facial flushing, elevated blood
pressure, and changes to existing moles. The FDA has warned against its use. PT-141/bremelanotide was specifically designed to be more targeted and safer than Melanotan II.13

WHAT TO KNOW

KEY TAKEAWAYS:

• PT-141/bremelanotide works through the brain’s melanocortin system — a completely different approach than Viagra-type drugs.
• Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women.
• Early research showed effects in men with ED, including non-responders to sildenafil.
• Common side effects include nausea and flushing.
• Melanotan II (the precursor) is NOT FDA-approved and has safety concerns.
• PT-141 as a research peptide is sold for laboratory purposes only.
• All sexual health concerns should be discussed with a qualified healthcare provider.

REFERENCES

1. Shifren JL, et al. Sexual problems and distress in United States women. Obstet Gynecol. 2008;112(5):970-978.
2. Selvin E, et al. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151-157.
3. Catania A, et al. The melanocortin system in control of inflammation. ScientificWorldJournal. 2010;10:1840-1853.
4. Van der Ploeg LH, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA. 2002;99(17):11381-11386.
5. Dorr RT, et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide. Life Sci. 1996;58(20):1777-1784.
6. Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. J Urol. 1998;160(2):389-393.
7. Kingsberg SA, et al. Bremelanotide for the treatment of HSDD: RECONNECT Phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
8. Simon JA, et al. Efficacy and safety of bremelanotide for HSDD. Obstet Gynecol. 2019;134(5):899-908.
9. Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide. J Sex Med. 2006;3(4):628-638.
10. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder. J Sex Med. 2008;5(4):887-897.
11. FDA. Vyleesi (bremelanotide) prescribing information. 2019.
12. AMAG Pharmaceuticals. Vyleesi clinical data summary. 2019.
13. FDA. FDA warns consumers about certain substances marketed as dietary supplements. 2009.

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY

This document is intended solely for educational purposes to increase awareness of emerging scientific research. It does not constitute medical advice and should not be used to make healthcare decisions.
Regulatory Status: Bremelanotide (Vyleesi) is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 is a research peptide sold for laboratory and educational purposes only and is NOT FDA-approved. Melanotan II is NOT FDA-approved for any use and the FDA has warned against its use.
All healthcare decisions should be made in consultation with qualified medical professionals.
This publication is part of an ongoing educational series designed to promote scientific literacy and awareness of developments in health research.